Stifel initiated coverage on Janux Therapeutics with a new price target
$JANX
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $45.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 9/17/2025 | $47.00 | Overweight | Barclays |
| 9/10/2025 | $45.00 | Buy | Stifel |
| 9/10/2025 | $100.00 | Buy | Truist |
| 9/4/2025 | $72.00 | Buy | Guggenheim |
| 8/19/2025 | $42.00 | Overweight | Piper Sandler |
| 7/11/2025 | $65.00 | Outperform | Raymond James |
| 12/3/2024 | $82.00 → $100.00 | Buy | BTIG Research |
Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company's proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B cells in blood and tissue. JANX011 is the first clinical candidate from Janux's proprietary ARM platform, which is designed to deliver sustained target B-cell depletion by harnes
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i
S-8 - Janux Therapeutics, Inc. (0001817713) (Filer)
10-K - Janux Therapeutics, Inc. (0001817713) (Filer)
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
3 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Wolfe Research initiated coverage of Janux Therapeutics with a rating of Peer Perform
Barclays initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $47.00
Stifel initiated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $45.00
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica